Naoya Sato

Dr. Naoya Sato

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
MGMitsukazu Gotoh
Mitsukazu Gotoh
NSNaoya Sato
Naoya Sato
TATsuyoshi Abe
Tsuyoshi Abe
NSNobuyasu Suzuki
Nobuyasu Suzuki
MWMitsuru Waragai
Mitsuru Waragai
AAAyaka Azami
Ayaka Azami
Intrahepatic splenosis (IHS) is the autotransplantation of splenic tissue that mostly develops after abdominal injury and is often misdiagnosed as hepatocellular carcinoma (HCC) because of similarities in radiological features. We had an opportunity to treat an extremely rare case of intrahepatic splenosis, which were found in a patient without any history of splenic injury. To the best of our knowledge, this is the first such case report in the world. A 58-year-old man with chronic hepatitis C was referred to our hospital for further examination of liver function abnormality. Abdominal ultrasonography incidentally revealed a low echoic tumor in the posterior segment of the liver, with high echoic capsule, which is possibly different from tumor capsule of HCC, known as halo. Abdominal contrast-enhanced computed tomography and gadoxetic acid-enhanced magnetic resonance imaging showed that the tumor had an inhomogeneous enhancement in the arterial phase and diminished enhancement in the equilibrium phase, diagnosed as HCC. The patient underwent right lateral segmentectomy of the liver, and histopathological study confirmed a diagnosis of intrahepatic splenosis. This case presents a new understanding of IHS in a patient without any splenic injury. We also focused on the differences in echo patterns of the tumor capsule between HCC and IHS, which can be used to efficiently diagnose IHS.

14 August 2021 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
NSNaoya Sato
Naoya Sato
AKAkira Kenjo
Akira Kenjo
SSSeiko Suzushino
Seiko Suzushino
TKTakashi Kimura
Takashi Kimura
RORyo Okada
Ryo Okada
SMShigeru Marubashi
Shigeru Marubashi

23 April 2018 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
NSNaoya Sato
Naoya Sato
AKA. Kenjo
A. Kenjo
TKT. Kimura
T. Kimura
ROR. Okada
R. Okada
TIT. Ishigame
T. Ishigame
SMShigeru Marubashi
Shigeru Marubashi

1 December 2000 in Molecular Brain Research
Verified
Journal Article
Closed access
TMTakashi Morihara
Takashi Morihara
TKTaiichi Katayama
Taiichi Katayama
NSNaoya Sato
Naoya Sato
TYTakunari Yoneda
Takunari Yoneda
TMTakayuki Manabe
Takayuki Manabe
MTMasaya Tohyama
Masaya Tohyama

1 January 2020 in FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
Verified
Journal Article
Open access
PDF file
NSNaoya Sato
Naoya Sato
TKTakashi Kimura
Takashi Kimura
AKAkira Kenjo
Akira Kenjo
YKYasuhide Kofunato
Yasuhide Kofunato
RORyo Okada
Ryo Okada
SMShigeru Marubashi
Shigeru Marubashi
Early intra-abdominal infection (IAI) following pancreaticoduodenectomy (PD) is an initial event relating to morbidities caused by postoperative pancreatic fistula (POPF). The aims of this study were to determine factors associated with IAI, and to investigate its impact on postoperative outcome.Consecutive patients, 113 in total, who underwent PD at Fukushima Medical University Hospital between January 2012 and September 2017 were included in this retrospective study. IAI was defined by positive bacterial culture from intra-abdominal drainage fluid any time through postoperative day 3 (POD3). Logistic regression analysis was used to identify the relevant factors associated with IAI. The clinical impact of the POD3 infection indicators related to POPF were assessed by multivariate analysis.The incidence of IAI, POPF, and mortality were 36.1%, 36.1%, and 0%, respectively. Independent factors associated with IAI were preoperative biliary drainage (PBD) (OR = 2.91, CI = 1.16-7.33, p = 0.023) and soft pancreas (OR = 8.67, CI = 2.37-31.77, p = 0.001). Among infection markers on POD3, the significant factors for POPF were CRP (OR = 1.18, CI = 1.08-1.30, p < 0.001), IAI (OR = 7,37, CI = 2.53-21.5, p < 0.001), and drain amylase (OR = 1.00, CI = 1.00-1.01, p = 0.001).In conclusion, PBD, soft pancreas, and higher age were associated with IAI. IAI has a significantly negative impact on postoperative outcome.

15 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSNaoya Sato
Naoya Sato
SMShigeru Marubashi
Shigeru Marubashi
Allogeneic islet transplantation has become an effective treatment option for severe Type 1 diabetes with intractable impaired awareness due to hypoglycemic events. Although current immunosuppressive protocols effectively prevent the acute rejection associated with initial T cell activation in recipients, chronic rejection has remained an obstacle for achieving long-term allogeneic islet engraftment. The development of donor-specific immune tolerance to the allograft is the ultimate goal given its potential ability to overcome chronic rejection and disregard the need for maintenance immunosuppression, which may be toxic to islet grafts. Recently, a breakthrough in tolerance induction during allogeneic islet transplantation using apoptotic donor lymphocytes (ADLs) in a non-human primate model had been reported. Several studies have suggested that the clonal depletion, anergy, and expansion of the antigen-specific regulatory immune network are the mechanisms for donor-specific tolerance with ADLs, which act synergistically to induce robust transplant tolerance. This achievement represents a huge step forward toward the clinical application of immune tolerance induction. We herein summarize the reported operational induction therapies in islet transplantation using the ADLs. Moreover, a few obstacles for the engraftment of transplanted islets, such as islet immunogenicity and instant blood-mediated response, which need to be resolved in the future, are also discussed.